Premium
Serum levels of variants of transthyretin down‐regulation in cholangiocarcinoma
Author(s) -
Liu Liyun,
Wang Jianing,
Liu Bo,
Dai Songwei,
Wang Xiaomin,
Chen Junzhou,
Huang Lingyun,
Xiao Xueyuan,
He Dacheng
Publication year - 2008
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.21661
Subject(s) - transthyretin , medicine , gastroenterology , western blot , pathology , chemistry , biochemistry , gene
Background Cholangiocarcinoma (CC) is devastating neoplasm and very few specific biomarkers could be used in clinical diagnosis. A study was taken to find novel serum biomarkers for CC. Methods Surface enhanced laser desorption/ionization (SELDI) technology was used to analyze 427 serum samples including 56 CCs, 49 hepatobiliary diseases, 269 other cancer control, and 53 healthy individuals. The candidates were isolated and identified by SDS–PAGE, ESI/MS‐MS, Western blot, and immunoprecipitation. Liver functions of CC patients were examined and enzyme‐linked immunosorbent assay (ELISA) of transthyretin (TTR) and CA19‐9 were further performed in some sets of serum samples. Results 13.76, 13.88, and 14.04 k m/z peaks in sera were significantly decreased in CC compared with the control groups ( P < 0.001). Subsequently, these three peaks were identified as native TTR and its two variants. ELISA assay indicated that TTR levels were consistent with SELDI analysis in CC compared with healthy control and benign diseases of hepatobiliary ( P < 0.001). Liver function test levels were obviously elevated for CC patients. TTR combining with CA19‐9 to differentiate CC from benign hepatobiliary diseases showed sensitivity and specificity were 98.2% and 100%, respectively. Conclusion The levels of TTR were significantly down‐regulated in sera of CC patients and may be complementary markers of CA19‐9 in diagnosis for CC. J. Cell. Biochem. 104: 745–755, 2008. © 2008 Wiley‐Liss, Inc.